Kimberly Oja
Adult Health · Walnut Creek, CANPI 1396245064
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,866 and has fallen 63.7% since, to $677 in 2025. Among adult health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$616
- Astellas Pharma US Inc$551
- Urogen Pharma, Inc.$422
- Bayer$387
- Merck$382
- Bluewind Medical$359
- plus $3K from 37 others
What the payments were for
- Food & beverage$5,57597%
- Education$2003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REVI$298
- AQUABEAM SYSTEM$146
- Veozah$125
- JELMYTO$101
How this compares
$5,775 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 151 | $153,372 |
| GemtesaVibegron | 104 | $88,041 |
| Methenamine Hippurate | 85 | $8,979 |
| Estradiol | 59 | $8,441 |
| Testosterone | 32 | $6,773 |
| Potassium Citrate ErPotassium Citrate | 40 | $3,909 |
| Finasteride | 190 | $3,042 |
| Testosterone Cypionate | 40 | $1,895 |
| Tamsulosin Hcl | 122 | $1,697 |
| Desmopressin Acetate | 22 | $1,662 |
| Oxybutynin Chloride ErOxybutynin Chloride | 49 | $1,335 |
| Solifenacin Succinate | 26 | $993 |
| Trospium Chloride ErTrospium Chloride | 14 | $910 |
| Trospium Chloride | 30 | $893 |
| Allopurinol | 57 | $835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $551 | $153,372151 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $125 | $88,041104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.
Other adult health in Walnut Creek
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
- Lisa HinemanLos Angeles$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.